2013
Written Informed Consent for Living Kidney Donors: Practices and Compliance With CMS and OPTN Requirements
Thiessen C, Kim YA, Formica R, Bia M, Kulkarni S. Written Informed Consent for Living Kidney Donors: Practices and Compliance With CMS and OPTN Requirements. American Journal Of Transplantation 2013, 13: 2713-2721. PMID: 24020884, DOI: 10.1111/ajt.12406.Peer-Reviewed Original ResearchConceptsConsent formKidney donorsKidney donor evaluationLiving Kidney DonorsKidney transplantRoutine followTransplant centersDonor evaluationUS CentersOPTN policyOrgan procurementHealth problemsInformed consentInformed consent practicesPrior yearSurgeryDonor consentConsentConsent practicesDonorsComplicationsTransplantComplianceFollowYears
2006
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period
Formica RN, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrology Dialysis Transplantation 2006, 21: 1389-1394. PMID: 16431893, DOI: 10.1093/ndt/gfk058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmlodipineBlood Pressure DeterminationChi-Square DistributionDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansHypertensionKidney Failure, ChronicKidney TransplantationLosartanMaleMiddle AgedProbabilityRisk AssessmentSeverity of Illness IndexTreatment OutcomeConceptsRenal transplant recipientsPost-transplant periodEarly post-transplant periodARB useUse of ARBInitial therapyCCB groupImmediate post-transplant periodPost-transplant erythrocytosisPost-transplant hypertensionRisk of hyperkalaemiaPost-transplant managementSerum creatinine levelsChronic kidney diseaseII receptor blockersCalcium channel blockersNumber of patientsAldosterone systemARB groupKidney transplantationRenal transplantationTransplant recipientsCreatinine levelsRenal functionBlood pressure
2002
Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate
Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate. American Journal Of Transplantation 2002, 2: 62-67. PMID: 12095058, DOI: 10.1034/j.1600-6143.2002.020111.x.Peer-Reviewed Original ResearchConceptsBone mineral densityHigh bone turnoverRenal transplant patientsBone lossBone turnoverTransplant patientsTotal femurLumbar spineLong-term renal transplant patientsLong-term renal transplant recipientsBiochemical markersBiochemical parametersGood renal functionGroup A patientsRenal transplant recipientsBone turnover markersRegional bone mineral densityTreatment of osteoporosisSerum alkaline phosphataseFirst yearBisphosphonate therapyTransplant recipientsAlendronate therapyRenal functionA patients